ライフサイエンスコーパス: SGA

1 SGA C (OR: 2.12; 95% CI: 1.24, 3.93) and HGS (OR: 0.96;

2 SGA fetuses defined by either the individualized or ultr

3 SGA infants with catch-up growth in the first 3-6 mo had

4 SGA uses the overlap-based string graph model of assembl

5 SGA, HGS, and food intake were independent predictors of

6 SGAs showed trend-level superiority for dropout owing to

7 SGAs were also superior regarding relapse at 3, 6 and 12

8 5.6%) preterm live-births and 187,966 (9.1%) SGA live-births.

9 iod (LMP), and early ultrasound (n = 1,135), SGA subjects' ultrasound GA was 5.5 days less than their

10 ipsychotic drugs (9,777 FGA users and 21,164 SGA users) aged 65 years or older, and who were enrolled

11 .1%) preterm, 132 (8.8%) LBW, and 123 (8.2%) SGA births, and the mean birth weight was 3245.3 g (95%

12 ated by bisulfite pyrosequencing (30 AGA, 21 SGA) and also analyzed in cord blood.

13 (7.6%) preterm, 68 (6.4%) LBW, and 99 (9.3%) SGA births, and the mean birth weight was 3308.5 g (95%

14 .8%) preterm, 236 (7.4%) LBW, and 267 (8.4%) SGA births.

15 .2; 95% confidence interval [CI], 1.1, 1.4), SGA (AOR, 1.8; 95% CI, 1.6, 2.1) and SB (AOR, 1.5; 95% C

16 Among 107,551 SGA initiators and 1,221,434 noninitiators, the risk for

17 er odds of PTD (AOR, 1.4; 95% CI, 1.2, 1.8), SGA (AOR, 1.5; 95% CI, 1.2, 1.9), and SB (AOR, 2.5; 95%

18 re categorized as small for gestational age (SGA) (<10th percentile) or large for gestational age (LG

19 the incidence of small for gestational age (SGA) and large for gestational age (LGA), defined as bir

20 ence for defining small for gestational age (SGA) at birth has gained popularity in recent years.

21 preterm delivery; small for gestational age (SGA) baby; need for the neonatal intensive care unit; do

22 rd trimesters for small-for-gestational age (SGA) newborns.

23 live births born small for gestational age (SGA) or preterm and mean birth weight.

24 as represented by small for gestational age (SGA) status.

25 4.4%, and that of small-for-gestational age (SGA) was 70.5%.

26 m delivery (PTD), small for gestational age (SGA), and neonatal death (NND).

27 tal malformation, small for gestational age (SGA), birth injury, low Apgar score (</=8), and neonatal

28 ey determinant of small for gestational age (SGA), but some knowledge gaps remain, particularly regar

29 t: preterm birth, small for gestational age (SGA), low birth weight (LBW), continuous birth weight, a

30 eonatal sequelae [small for gestational age (SGA), microcephaly, CHD, intellectual or developmental d

31 h birth outcomes [small for gestational age (SGA), preterm birth (PTB)].In an observational study in

32 of children born small for gestational age (SGA), we measured the mRNA expression levels of p73 and

33 ong children born small for gestational age (SGA).

34 preterm birth and small for gestational age (SGA).

35 ) of infants born small for gestational age (SGA).

36 ession to examine small for gestational age (SGA).

37 birth, and being small-for-gestational age (SGA).

38 preterm delivery; small for gestational age (SGA); need for neonatal intensive care unit (NICU); new

39 (<37 weeks), small size for gestational age (SGA; <10th percentile of weight for gestational age) or

40 , and the risk of small for gestational age (SGA; ie, a birth weight of <10th percentile for gestatio

41 t (n = 918), term small-for-gestational-age (SGA) (n = 353), and a continuous measure of birth weight

42 Small-for-gestational-age (SGA) and preterm births were examined as secondary outco

43 dies finding that small-for-gestational-age (SGA) birth is associated with increased adiposity in chi

44 egnancy outcomes (small-for-gestational-age (SGA) birth, large-for-gestational-age (LGA) birth, spont

45 pre-eclampsia and small-for-gestational-age (SGA) birth, which are indicative of uteroplacental dysfu

46 Risks of small-for-gestational-age (SGA) births (<10th percentile), chorioamnionitis, preter

47 ences the risk of small-for-gestational-age (SGA) births and other aspects of fetal growth.

48 l weight gain and small-for-gestational-age (SGA) births, large-for-gestational-age (LGA) births, spo

49 births (PTBs) or small-for-gestational-age (SGA) births.

50 term delivery and small-for-gestational-age (SGA) births.

51 ional age (GA) in small-for-gestational-age (SGA) fetuses may underestimate gestational duration and

52 hypertension, and small-for-gestational-age (SGA) infants are complications in about 15% of all nulli

53 erentiate healthy small-for-gestational-age (SGA) infants from pathologically small infants in a huma

54 creening test for small-for-gestational-age (SGA) infants, and whether the risk of morbidity associat

55 with outcomes in small-for-gestational-age (SGA) infants.

56 preeclampsia; and small-for-gestational-age (SGA) neonate (birthweight below the fifth percentile).

57 (PE), birth of a small-for-gestational-age (SGA) newborn (<10th percentile), placental abruption, or

58 utero leading to small-for-gestational-age (SGA) newborns is associated with increased neonatal morb

59 ivery, birth of a small-for-gestational-age (SGA) or large-for-gestational-age (LGA) infant, and post

60 preeclampsia and small-for-gestational-age (SGA) pregnancies.

61 onal-age (AGA) or small-for-gestational-age (SGA) to identify new genes related to fetal growth and n

62 preterm birth or small-for-gestational-age (SGA), or both--is the biggest risk factor for more than

63 ks to <37 weeks), small-for-gestational-age (SGA; babies with birthweight in the lowest third percent

64 [GA] at delivery, small for gestational age [SGA], multiple births, and male sex).

65 [LBW], <2500 g), small-for-gestational-age [SGA], and BW z scores [BWZ]) in HIV-exposed uninfected i

66 c to second-generation antipsychotic agents (SGAs), as first-generation medications suppress the loco

67 were active from steroidal glycol-alkaloid (SGA), lignin and flavonoid biosynthetic pathways.

68 rch for a set of somatic genome alterations (SGA) that likely perturbed the signal, that is, the cand

69 well known that somatic genome alterations (SGAs) affecting the genes that encode the proteins withi

70 ainly caused by somatic genomic alterations (SGAs) that perturb pathways regulating metastasis-releva

71 tiating only SGAs, the risk was higher among SGA initiators who used antidepressants concomitantly at

72 quasispecies by single-genome amplification (SGA) and documented that a single virus variant establis

73 Single-genome amplification (SGA) was used to identify full-length T/F genomes presen

74 mined following single-genome amplification (SGA).

75 f sampling than single-genome amplification (SGA).

76 ed by using the single-genome-amplification (SGA) method to independently obtain 302 sequences from 1

77 le, and had a relative risk of delivering an SGA infant with neonatal morbidity of 17.6 (9.2-34.0, p<

78 463, 0.724).Protection against delivering an SGA neonate offered by greater preconceptional or gestat

79 f vaccinated and 8.3% of unvaccinated had an SGA birth (adjusted RR, 1.00; 95% CI, 0.96-1.06).

80 The adjusted risk of an SGA birth was reduced in multivitamin users regardless o

81 as decreased in preeclampsia (P = 0.002) and SGA (P = 0.002) cases.

82 vs 17.7%; RR, 1.54; 95% CI, 1.05-2.25), and SGA status (9.2% vs 12.7%; RR, 1.51; 95% CI, 0.94-2.42).

83 priate for gestational age (AGA; n = 72) and SGA infants receiving BRF (n = 46) or FOF (n = 56), the

84 in 1%, preterm delivery occurred in 9%, and SGA neonate occurred in 10%.

85 r risks for prematurity, NICU admission, and SGA status compared with longer intervals.

86 Associations between each cytokine and SGA and preterm delivery were evaluated using log binomi

87 n of both preterm and term pre-eclampsia and SGA.

88 curs in normal pregnancy, pre-eclampsia, and SGA pregnancies.

89 weight, low birth weight (LBW, <2500 g), and SGA.

90 oth time points had a steady fall in LBW and SGA rate with age, similar to the pattern seen in white

91 and placebo groups nor did rates of LBW and SGA.

92 , SGA B = mild or moderate malnutrition, and SGA C = severe malnutrition), Nutrition Risk Screening (

93 lation of key genes from phenylpropanoid and SGA pathways along with WRKY and MYB in WRKY1 transgenic

94 expression was increased in preeclampsia and SGA cases and was decreased with birth weight and gestat

95 vel pathological feature of preeclampsia and SGA.

96 a US reference population), and preterm and SGA combinations.

97 e burden and risk of babies born preterm and SGA rather than with low birthweight could guide prevent

98 ity risk of babies who were both preterm and SGA was higher than that of babies with either character

99 (+) was independently associated with SB and SGA, and maternal hypertension during pregnancy with PTD

100 ferential mortality risk between FGA use and SGA use in older adults is unclear.

101 erence [MD], -6.50 [CI, -8.82 to -4.18]) and SGAs (MD, -3.84 [CI, -6.55 to -1.13]) reduced binge-eati

102 ting-related obsessions and compulsions, and SGAs reduced symptoms of depression (MD, -1.97 [CI, -3.6

103 in mortality risk between users of FGAs and SGAs may develop mostly through pathways that do not inv

104 ficacy of second-generation antidepressants (SGAs) versus most other treatments for this disorder.

105 Second-generation antipsychotics (SGAs) are increasingly used in the treatment of many psy

106 Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enro

107 (FGAs) and second-generation antipsychotics (SGAs) in treating schizophrenia.

108 Pooled second-generation antipsychotics (SGAs) were associated with shorter TTR (SMD=-0.27) and a

109 s compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regard

110 d larval stage of the short great appendage (SGA) arthropod (megacheiran) Leanchoilia illecebrosa fro

111 n low-income and middle-income countries are SGA.

112 roscopic screening, synthetic genetic array (SGA) analysis, and high-density transcript profiling to

113 used candidate and synthetic genetic array (SGA) approaches to more fully characterize SNARE-mediate

114 ele of HMT1 and the synthetic genetic array (SGA) methodology.

115 tion screens using synthetic genetic arrays (SGA) with gsk3 and amk2 as query mutants, the latter enc

116 1.2 to 5.0), mainly stillbirths assessed as SGA (IRR, 4.9; 95% CI, 2.2 to 11.0), and with preterm SG

117 Infants were categorized as SGA using the 1991 US birth weight reference, the 1999-2

118 admission were subjective global assessment (SGA; SGA A = well nourished, SGA B = mild or moderate ma

119 ; -6.4, p < 0.001) decrease in odds of being SGA was observed.

120 roaches to analyzing the association between SGA birth and adiposity outcomes (skinfold thicknesses a

121 proach yielded negative associations between SGA birth and all adiposity outcomes.

122 No associations were observed between SGA and exposure to combination ARV regimens.

123 he SGA prevalence and the risk ratio between SGA status and neonatal mortality, calculated using Pois

124 Children born SGA (birth weight <10th percentile) and those born large

125 Children born SGA had a significantly lower BMI, percentage body fat,

126 The 11.5-y-old Belarusian children born SGA were shorter, were thinner, and had less body fat th

127 ficantly (P < 0.001) higher in children born SGA.

128 ity measures intermediate between those born SGA without catch-up and those born AGA.

129 The incidence of both SGA and LGA significantly decreased during the study per

130 the sex and race-ethnicity-specific mean BW (SGA(2SD)), and macrosomia (BW ge 4500 g).

131 ethods-identified pathways were perturbed by SGA.

132 m, and a new assembler based on these called SGA (String Graph Assembler).

133 thout requiring inter-process communication, SGA provides the first practical assembler to our knowle

134 omized trials, lasting >/=6 months comparing SGAs with FGAs in schizophrenia.

135 utpoint than the 10th percentile in defining SGA.

136 as estimates of the RR of a woman to deliver SGA offspring when maternal tHcy exceeded the 90th perce

137 risk factors, in addition to GA at delivery, SGA, multiple births, and male sex.

138 n maternal PHIV status and preterm delivery, SGA, or LBW were observed.

139 fects a smaller number of neonates than does SGA, but is associated with a higher mortality risk.

140 al-oriented framework for identifying driver SGAs.

141 e ability to find informative sets of driver SGAs that likely constitute signaling pathways.

142 with second-generation antipsychotic drugs (SGAs).

143 Identifying drivers of metastasis, i.e. SGAs, sheds light on the metastasis mechanism and provid

144 These data implicate MC4R in extreme SGA-induced weight gain and related metabolic disturbanc

145 he individualized reference classified fewer SGA fetuses than the ultrasound reference, but the risks

146 decrease of 1.6% [95% CI, 1.5% to 1.7%] for SGA, 1.6% [95% CI, 1.5% to 1.8%] for LGA).

147 002) but was not significantly different for SGA initiators who were concomitantly using stimulants.

148 Except for SGA, all neonatal sequelae were more frequent in untreat

149 mesters are the time windows of interest for SGA (fetal growth).

150 for gestational age and screen positive for SGA an ultrasonographic estimated fetal weight of less t

151 as a good biomarker of the clinical risk for SGA children to remain short in adulthood.

152 e associated with a small increased risk for SGA offspring.

153 egimens were associated with higher risk for SGA; ZDV-3TC-NVP was associated with higher risk of stil

154 tion, baseline glucose and lipid testing for SGA-treated patients was infrequent and showed little ch

155 r, we introduce a novel method to search for SGAs driving breast cancer metastasis to the lung.

156 ermethylated in placenta and cord blood from SGA newborns, whereas GPR120 (related to free fatty acid

157 South Asia has the highest SGA rates and sub-Saharan Africa has the highest preterm

158 Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%

159 es (n = 72), ii) preeclampsia (n = 52), iii) SGA (n = 66), and iv)preeclampsia with SGA (n = 31).

160 Improved SGA score in the Regul8 groups may indicate some overall

161 close whether the endocrine abnormalities in SGA-FOF infants can serve as early markers of an unfavor

162 A change in SGA drug selection consistent with intentions to reduce

163 Changes in SGA prescribing practices were similarly evaluated.

164 We found a narrowing of disparities in SGA and LGA incidence across different maternal educatio

165 of p73 and IGFBP3 are significantly lower in SGA children compared with controls and, in particular,

166 73 mRNA expression is significantly lower in SGA children with respect to height.

167 A reduction in SGA births, but not preterm birth or perinatal mortality

168 rved a greater-than-one-quarter reduction in SGA prevalence and no significant change in the associat

169 s and antidepressants, as well as individual SGAs.

170 n=61.9+/-22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding st

171 Compared with AGA-BRF infants, SGA-BRF infants had normal HMW adiponectin and IGF-I lev

172 llitus was increased among youths initiating SGAs and was highest in those concomitantly using antide

173 e-control study (May 2002-June 2005) of Iowa SGA births and preterm deliveries identified from birth

174 nitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related ps

175 In the unadjusted model, SGA subjects required a correction of +1.5 weeks to the

176 negative interactions than the double mutant SGA screens and uncovered additional genetic network inf

177 The triple-mutant SGA screen showed higher number of negative interactions

178 bined outcome (early preterm delivery, NICU, SGA).

179 l" combined outcome (preterm delivery, NICU, SGA); and "severe" combined outcome (early preterm deliv

180 hinner, and had less body fat than their non-SGA peers, irrespective of postnatal weight gain.

181 bal assessment (SGA; SGA A = well nourished, SGA B = mild or moderate malnutrition, and SGA C = sever

182 The former group had the highest observed SGA prevalence.

183 We 1) studied the association of SGA birth with adiposity, adjusting for baseline covaria

184 nology more readily than body composition of SGA infants.

185 Sensitivity for detection of SGA infants was 20% (95% CI 15-24; 69 of 352 fetuses) fo

186 fetal biometry roughly tripled detection of SGA infants.

187 to estimate the controlled direct effect of SGA birth.

188 We assessed the effects of SGA birth and weight gain in early infancy on adiposity

189 ssion levels of p73 and IGFBP3 in a group of SGA children.

190 with AGA-BRF infants, the catchup growth of SGA infants was confined to lean mass, independently of

191 onal duration and therefore the incidence of SGA birth.

192 Moreover, the occurrence of SGA, microcephaly, and IDDs was significantly related to

193 I women significantly increased the odds of SGA(2SD), whereas a GWG from 0.1 to 4.9 kg was not assoc

194 PFUnDA were associated with elevated odds of SGA; and PFDeA, PFUnDA, and PFDoDA were associated with

195 ction as indicated by a composite outcome of SGA and pre-eclampsia.

196 error correction and assembly performance of SGA on 1.2 billion sequence reads from a human genome, w

197 rs of AEDs in monotherapy, the prevalence of SGA ranged from 7.3% for lamotrigine to 18.5% for topira

198 l growth as shown by a reduced prevalence of SGA.

199 nts were routine.In 2004, the proportions of SGA decreased with longer exposure to the new ration: no

200 to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.79-1.43; 50 exposed cases).

201 amma was associated with a decreased risk of SGA birth (RR = 0.78, 95% CI: 0.61, 1.01).

202 ciated with a 2- to 3-fold increased risk of SGA birth and a significantly lower birth weight, birth

203 or GWG was associated with an excess risk of SGA birth, while high GWG combined with each of these ch

204 was also related to birth length and risk of SGA birth.

205 amin use was associated with reduced risk of SGA births and PTBs in nonoverweight women.

206 tamin B-12:folate ratio had a higher risk of SGA outcome than did those in the highest tertile (adjus

207 The risk of SGA tended to decrease with increasing GWG in both parit

208 loss was associated with an elevated risk of SGA, iPTB, and sPTB, and a high weight gain tended to in

209 dependently associated with a higher risk of SGA.

210 regnancy was not associated with the risk of SGA/spontaneous abortions/overall malformations.

211 gestational weight gain to balance risks of SGA, LGA, sPTB, and iPTB may vary by severity of obesity

212 Next, we search for a set of SGA events that carries strong information with respect

213 ranscriptomic module, we search for a set of SGA genes (driver modules) such that genes in each drive

214 se-response effect across 2 subcategories of SGA (P < 0.001 for all comparisons).

215 fetal growth velocity identified a subset of SGA fetuses that were at increased risk of neonatal morb

216 antidepressants concomitantly at the time of SGA initiation (OR, 1.54; 95% CI, 1.17-2.03; P = .002) b

217 sing weight gain associated with 12 weeks of SGA treatment in patients undergoing first exposure to a

218 nserin and MDL-11939 replicate the effect of SGAs, repressing the activity in WT mice at a dosage tha

219 mice to the locomotor suppressive effects of SGAs, and suggest that 5HT(2A)Rs may also contribute to

220 elevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whethe

221 data files, initiators and noninitiators of SGAs were identified in each month.

222 verall, this study highlights vital roles of SGAs as phytoalexins and phenylpropanoids along with lig

223 Superiority of SGAs regarding relapse was modest (NNT=17), but confirme

224 light on how previously published studies on SGA status may be reinterpreted with the introduction of

225 There was no effect of vaccine on SGA or mean birth weight.

226 controlled for age, sex, and diagnosis, only SGA C (OR: 2.19; 95% CI: 1.28, 3.75), HGS (OR: 0.98; 95%

227 Compared with youths initiating only SGAs, the risk was higher among SGA initiators who used

228 placental bed of preterm preeclampsia and/or SGA births than in control cases (48.7% versus 17.9%; P

229 ood samples from women with pre-eclampsia or SGA were analysed from the time of disease presentation

230 ernal H1N1 influenza immunization and LBW or SGA.

231 posure, a diagnosis of diabetes mellitus, or SGA use during a 1-year look-back period were ineligible

232 tensive disorders of pregnancy or preterm or SGA birth, although a small but statistically significan

233 en any multivitamin use and PTBs (<37 wk) or SGA births (birth weight adjusted for gestational age >2

234 ated levels of HMW adiponectin (particularly SGA-FOF1) and IGF-I (particularly SGA-FOF2).

235 rticularly SGA-FOF1) and IGF-I (particularly SGA-FOF2).

236 idual outcomes, including any PE, severe PE, SGA <10th percentile, SGA <5th percentile, preterm deliv

237 ing any PE, severe PE, SGA <10th percentile, SGA <5th percentile, preterm delivery <37 weeks, and pre

238 We also performed SGA screen with the amk2 gsk3 double mutant as a query.

239 There was a lower risk of pre-eclampsia plus SGA combined (13.6%) at 25(OH)D concentrations >75 nmol/

240 The pooled SGA prevalence was 23.7% (95% CI, 16.5%-31.0%) using the

241 4.9; 95% CI, 2.2 to 11.0), and with preterm SGA births (relative risk 3.0; 95% CI, 2.1 to 4.4).

242 Preterm-SGA babies totalled 2.8 million births in low-income and

243 ll for gestational age (term-SGA and preterm-SGA), and the relation to low birthweight (<2500 g), in

244 in south Asia, and the prevalence of preterm-SGA infants ranged from 1.2% in north Africa to 3.0% in

245 Prevalence of preterm-SGA infants was calculated from meta-analyses.

246 bies, 59% were term-SGA and 41% were preterm-SGA.

247 pregnancy was associated with increased PTD, SGA, and SB.

248 V was significantly associated with SB, PTD, SGA, and NND.

249 rnal hypertension during pregnancy with PTD, SGA, and SB.

250 testing for all patients starting to receive SGA drugs.

251 We regarded SGA as a birthweight of less than the 10th percentile fo

252 ntion strategies should focus on both severe SGA and severe LGA pregnancies.

253 associations were stronger with more severe SGA and LGA (<5th and >95th percentile).

254 sion were subjective global assessment (SGA; SGA A = well nourished, SGA B = mild or moderate malnutr

255 pregnancy BMI or GWG and macrosomic, small- (SGA) and large- (LGA) for-gestational-age infants.

256 weeks) and small for gestational age status (SGA) among infants exposed prenatally to AEDs when used

257 ient to indicate that genes affected by such SGAs are in common pathways.

258 by early ultrasound in women with suspected SGA fetuses.

259 Babies who are term SGA low birthweight (10.4 million in these regions) are

260 babies born small for gestational age (term-SGA and preterm-SGA), and the relation to low birthweigh

261 The prevalence of term-SGA babies ranged from 5.3% of livebirths in east Asia t

262 s) were used to model the prevalence of term-SGA births.

263 illion low-birthweight babies, 59% were term-SGA and 41% were preterm-SGA.

264 In particular, our analyses revealed that SGA affecting TP53, PTK2, YWHAZ, and MED1 perturbed a se

265 Our results suggested that SGAs have a benefit for the treatment of delirium with r

266 For each study, we compared the SGA prevalence and the risk ratio between SGA status and

267 s fine details of the main feeding limb, the SGA, which are unknown in the adult of the same species.

268 ight or BMI reversed (i.e., to positive) the SGA-adiposity association.

269 However, no studies have used the SGA strategy to identify vaginally transmitted virus(es)

270 y exhibit mutual exclusivity, in which these SGAs usually do not co-occur in a tumor.

271 percentage of neonatal death attributable to SGA.

272 f delivering prematurely and giving birth to SGA newborns.

273 etabolic adverse effects have been linked to SGA use in youths, estimating the risk for type 2 diabet

274 from the preceding time] and were related to SGA risk with the use of Poisson regression with confoun

275 ency of periconceptional multivitamin use to SGA births and PTBs and its clinical presentations (ie,

276 in ultrasound and LMP dating underestimated SGA birth by 12.9% and overestimated preterm delivery by

277 Unfortunately, SGAs are often associated with substantial weight gain,

278 We used SGA to amplify 227 partial env sequences from a SIVmac25

279 n and HGS has a wide range of normal values, SGA is the single best predictor and should be advocated

280 risks associated with the use of FGAs versus SGAs as mediated by stroke on the risk ratio scale, as w

281 Clear benefits of FGAs versus SGAs for treating schizophrenia remain inconclusive beca

282 cluding very preterm birth (<32 weeks), very SGA (<3rd percentile of weight for gestational age), sti

283 l effect of antipsychotic drug type (FGA vs. SGA) on mortality risk (risk ratio = 1.15, 95% CI: 1.08,

284 0.2% were spontaneous preterm, and 7.3% were SGA.

285 clampsia was 3.8%, and 10.7% of infants were SGA.

286 Pooled RRs for babies who were SGA (with birthweight in the lowest tenth percentile of

287 nectin and IGF-I levels at 4 months, whereas SGA-FOF infants had elevated levels of HMW adiponectin (

288 s on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-pot

289 ssified by conducting the same analysis with SGA data.

290 nly conditional zwt+7 mo was associated with SGA and only in women with values >-0.5 (RR: 0.579; 95%

291 rths studied, stillbirth was associated with SGA based on population, ultrasound, and individualized

292 individual-level traits) are associated with SGA risk in rural Gambia.The sample comprised 670 women

293 G from 0.1 to 4.9 kg was not associated with SGA(2SD) and did not decrease the odds of macrosomia.

294 statistically significantly associated with SGA, birth weight, and BWPGA.

295 io = 1.15, 95% CI: 1.08, 1.22) compared with SGA use, but stroke explained little (2.7%) of the obser

296 iii) SGA (n = 66), and iv)preeclampsia with SGA (n = 31).

297 int had a consistent nonlinear relation with SGA risk.

298 were also significantly higher in women with SGA than in controls at the time of disease detection (n

299 ts in the discovery cohort were treated with SGAs for 12 weeks.

300 re generally higher in patients treated with SGAs.